Zomedica Other Assets vs Property Plant And Equipment Net Analysis
ZOM Stock | USD 0.18 0.01 4.53% |
Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Other Assets and its Property Plant And Equipment Net accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
Other Assets vs Property Plant And Equipment Net
Other Assets vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Other Assets account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Zomedica Pharmaceuticals' Other Assets and Property Plant And Equipment Net is 0.19. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Other Assets and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Other Assets i.e., Zomedica Pharmaceuticals' Other Assets and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Other Assets
Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 21st of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.30, while Issuance Of Capital Stock is likely to drop 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.5M | 6.7M | 6.3M | 6.6M | Interest Income | 321.1K | 2.5M | 5.6M | 5.9M |
Zomedica Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Zomedica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zomedica Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
Other Current Liab | 1.0 | 1.2M | 501.5K | 265K | 172K | 163.4K | |
Total Current Liabilities | 2.1M | 2.0M | 4.3M | 7.8M | 9.0M | 9.5M | |
Total Stockholder Equity | 2.1M | 51.1M | 270.9M | 267.4M | 240.0M | 252.0M | |
Net Debt | (510.6K) | (60.1M) | (193.6M) | (25.7M) | (10.2M) | (10.7M) | |
Retained Earnings | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (170.9M) | (162.4M) | |
Cash | 510.6K | 62.0M | 195.0M | 27.4M | 13.0M | 12.3M | |
Non Current Assets Total | 2.4M | 3.3M | 80.0M | 156.1M | 153.3M | 161.0M | |
Non Currrent Assets Other | (2.4M) | 1M | 659.1K | 453K | 1.1M | 1.1M | |
Cash And Short Term Investments | 510.6K | 62.0M | 195.0M | 115.1M | 90.5M | 95.0M | |
Liabilities And Stockholders Equity | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
Other Stockholder Equity | 3.6M | 2.8M | 9.3M | 23.7M | 29.9M | 31.4M | |
Total Liab | 2.1M | 15.1M | 9.5M | 12.2M | 13.2M | 13.8M | |
Total Current Assets | 1.8M | 62.9M | 200.4M | 123.5M | 99.9M | 104.9M | |
Net Receivables | 67.6K | 146.2K | 765.5K | 1.9M | 2.2M | 2.3M | |
Common Stock Shares Outstanding | 106.3M | 364.4M | 956.5M | 979.9M | 979.9M | 1.0B | |
Other Current Assets | 1.2M | 727.8K | 1.8M | 3.8M | 2.1M | 1.4M | |
Accumulated Other Comprehensive Income | 0.0 | 459.6K | 1.7K | (843K) | 48K | 59.2K | |
Common Stock | 38.6M | 104.8M | 381.0M | 381.0M | 342.9M | 325.7M | |
Net Tangible Assets | (10.4M) | 50.7M | 194.1M | 161.6M | 185.9M | 195.1M | |
Property Plant And Equipment Net | 1.8M | 1.9M | 2.5M | 9.2M | 25.3M | 26.6M | |
Accounts Payable | 2.1M | 1.2M | 3.2M | 6.7M | 7.7M | 8.1M | |
Common Stock Total Equity | 38.6M | 459.6 | 381.0M | 381.0M | 438.1M | 460.0M | |
Retained Earnings Total Equity | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (122.8M) | (116.6M) | |
Short Term Investments | 570.0K | 1.3M | 1.0M | 87.7M | 77.5M | 81.4M | |
Property Plant And Equipment Gross | 2.4M | 583.01 | 3.4M | 10.4M | 27.3M | 28.7M | |
Intangible Assets | 543.4K | 376.6K | 33.5M | 41.8M | 55.4M | 58.1M | |
Property Plant Equipment | 1.8M | 583.0K | 2.5M | 6.8M | 7.8M | 8.2M | |
Cash And Equivalents | 510.6K | 62.0M | 195.0M | 27.4M | 31.5M | 46.1M | |
Capital Surpluse | 3.6M | 14.8M | 9.3M | 23.7M | 27.2M | 28.6M | |
Net Invested Capital | (9.9M) | 51.6M | 270.9M | 267.4M | 240.0M | 130.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Zomedica Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.142 | Return On Assets (0.08) | Return On Equity (0.15) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.